← board
SCLX
distress 4/10 · elevated risk$7.23+3%today-61% from 52w high
Revenue
pre-revenue
Liquidity
$3M
Runway
1.0 yrs
Shares 1y
+22%
Price & events
+0.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
+2.8%
1D
-17.7%
1W
+5.1%
1M
+67.3%
3M
+5.7%
6M
+2.2%
1Y
-80.6%
2Y
-96.7%
5Y
-96.6%
All
Overview
- Market Cap
- $61.39M
- Volume
- 5.93K
- 52 Week Range
- $3.69 – $18.68
- Total Shares
- 8.49M
- Float Shares
- 5.69M
- Short %
- 2.96%
- % Held by Insiders
- 11.67%
- % Held by Institutions
- 13.10%
- RVOL
- 0.03x
- Beta
- 1.73
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 8,491,267 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2025-04-11D. Boral CapitalBuy → Hold
- 2025-04-02D. Boral CapitalBuy
- 2025-02-28D. Boral CapitalBuy
- 2025-01-27D. Boral CapitalBuy
- 2024-10-21HC Wainwright & Co.Buy
- 2024-10-16Alliance Global PartnersBuy
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.